my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
01-09-2006: LibraGen announced that it has signed a partnership agreement with the R&D department of Pierre Fabre Medicament, France's second largest independent pharmaceutical company. Under the terms of the agreement, LibraGen will use enzymatic technologies to optimize the synthesis of a molecule which is the main active ingredient of one of Pierre Fabre's medicines. This enzymatic production process bypasses the need for several stages of chemical synthesis, thus optimizing production costs and significantly improving environmental impact.
Watchlist
This is where you can add this news to your personal favourites
LibraGen signs partnership agreement with Pierre Fabre Medicament R&D
LibraGen announced that it has signed a partnership agreement with the R&D department of Pierre Fabre Medicament, France's second largest independent pharmaceutical company. Under the terms of the agreement, LibraGen will use enzymatic technologies to optimize the synthesis of a molecule wh ... more
LibraGen uses innovative and proprietary functional genomic technologies in combination with industrial expertises to develop new bioprocesses for the discovery of novel bioactives and the improvement of production processes of added value molecules. Libragen's competitive edge is embodied ... more
Olivier Bohuon Appointed Chief Executive Officer of Pierre Fabre SA
During its first meeting, the Board of Directors of Pierre Fabre SA chaired by Mr. Pierre Fabre appointed Olivier Bohuon as the company's Chief Executive Officer. Olivier Bohuon, 51, has until now been the executive vice-president of Abbott Corporation and president of its pharmaceutics di ... more
LibraGen signs partnership agreement with Pierre Fabre Medicament R&D
LibraGen announced that it has signed a partnership agreement with the R&D department of Pierre Fabre Medicament, France's second largest independent pharmaceutical company. Under the terms of the agreement, LibraGen will use enzymatic technologies to optimize the synthesis of a molecule wh ... more
Pierre Fabre Médicament is the 2nd largest independent French pharmaceutical laboratory, and orients its development on specifically targeted therapeutic lines. Investment in research has resulted in the discovery of new molecules, and this effort has enabled the firm to reinforce and empha ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
